Cardiovascular safety of stimulant medications for pediatric attention-deficit hyperactivity disorder

Clinical Pediatrics

Volumn 49, Issue 9, 2010, Pages 840-851

  Silva, Raul R ^a   Skimming, Jeffrey W ^b   Muniz, Rafael ^c  

^a NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^b PEDIATRIX MEDICAL GROUP   (United States)

^c NOVARTIS PHARMA AG   (Switzerland)

Author keywords

attention deficit hyperactivity disorder; cardiovascular adverse effects; stimulant medications

Indexed keywords

AMPHETAMINE DERIVATIVE; METHYLPHENIDATE;

ATTENTION DEFICIT DISORDER; DRUG FATALITY; DRUG SAFETY; ECG ABNORMALITY; ECHOCARDIOGRAPHY; ELECTROCARDIOGRAPHY; HEART RATE; HUMAN; HYPERTENSION; REVIEW; SIDE EFFECT;

ADOLESCENT; ADULT; AMPHETAMINES; ATTENTION DEFICIT DISORDER WITH HYPERACTIVITY; BLOOD PRESSURE; CARDIOVASCULAR SYSTEM; CENTRAL NERVOUS SYSTEM STIMULANTS; CHILD; DEATH, SUDDEN, CARDIAC; ELECTROCARDIOGRAPHY; HEART DISEASES; HEART RATE; HUMANS; METHYLPHENIDATE; MIDDLE AGED;

EID: 77955456675     PISSN: 00099228     EISSN: None     Source Type: Journal    
DOI: 10.1177/0009922810368289     Document Type: Review

References (62)

1. Spencer TJ, Biederman J., Mick E. Attention-deficit/ hyperactivity disorder: diagnosis, lifespan, comorbidities, and neurobiology. Ambul Pediatr. 2007; 7 (suppl 1). 73-81.
2. American Academy of Pediatrics. CoQI, Subcommittee on Attention-Deficit/Hyperactivity Disorder Clinical practice guideline: diagnosis and evaluation of the child with attention-deficit/hyperactivity disorder. Pediatrics. 2000; 105: 1158-1170.
3. Vetter VL, Elia J., Erickson C., et al. Cardiovascular monitoring of children and adolescents with heart disease receiving stimulant drugs: a scientific statement from the American Heart Association Council on Cardiovascular Disease in the Young Congenital Cardiac Defects Committee and the Council on Cardiovascular Nursing. Circulation. 2008; 117: 2407-2423.
4. Perrin JM, Friedman RA, Knilans TK Cardiovascular monitoring and stimulant drugs for attention-deficit/ hyperactivity disorder. Pediatrics. 2008; 122: 451-453.
5. American Academy of Pediatrics / American Heart Association. American Academy of Pediatrics/American Heart Association clarification of statement on cardiovascular evaluation and monitoring of children and adolescents with heart disease receiving medications for ADHD: May 16, 2008. J Dev Behav Pediatr. 2008; 29: 335.
6. Gould MS, Walsh BT, Munfakh JL, et al. Sudden death and use of stimulant medications in youths. Am J Psychiatry. 2009; 166: 992-1001.
7. Nissen SE ADHD drugs and cardiovascular risk. N Engl J Med. 2006; 354: 1445-1448.
8. Volkow ND, Wang GJ, Fowler JS, et al. Cardiovascular effects of methylphenidate in humans are associated with increases of dopamine in brain and of epinephrine in plasma. Psychopharmacology (Berl). 2003; 166: 264-270.
9. Foltin RW, Fischman MW, Levin FR Cardiovascular effects of cocaine in humans: laboratory studies. Drug Alcohol Depend. 1995; 37: 193-210.
10. Albertson TE, Derlet RW, Van Hoozen BE Methamphetamine and the expanding complications of amphetamines. West J Med. 1999; 170: 214-219.
11. Karch SB Cocaine cardiovascular toxicity. South Med J. 2005; 98: 794-799.
12. Pilgrim JL, Gerostamoulos D., Drummer OH, Bollmann M. Involvement of amphetamines in sudden and unexpected death. J Forensic Sci. 2009; 54: 478-485.
13. Findling RL, Biederman J., Wilens TE, et al. Short-and long-term cardiovascular effects of mixed amphetamine salts extended release in children. J Pediatr. 2005; 147: 348-354. (Pubitemid 41348714)
14. Findling RL, Short EJ, Manos MJ Short-term cardiovascular effects of methylphenidate and adderall. J Am Acad Child Adolesc Psychiatry. 2001; 40: 525-529.
15. Wilens TE, Spencer TJ, Biederman J. Short-and long-term cardiovascular effects of mixed amphetamine salts extended-release in adolescents with ADHD. CNS Spectr. 2005; 10 (suppl 15). 22-30. (Pubitemid 41513195)
16. Spencer T., Biederman J., Wilens T., et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2005; 57: 456-463.
17. Biederman J., Mick E., Surman C., et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2006; 59: 829-835.
18. Wilens TE, Hammerness PG, Biederman J., et al. Blood pressure changes associated with medication treatment of adults with attention-deficit/ hyperactivity disorder. J Clin Psychiatry. 2005; 66: 253-259.
19. Samuels JA, Franco K., Wan F., Sorof JM Effect of stimulants on 24-h ambulatory blood pressure in children with ADHD: a double-blind, randomized, cross-over trial. Pediatr Nephrol. 2006; 21: 92-95.
20. Silva R., Muniz R., McCague K., Childress A., Brams M., Mao A. Treatment of children with attention-deficit/ hyperactivity disorder: results of a randomized, multi-center, double-blind, crossover study of extended-release dexmethylphenidate and d,l-methylphenidate and placebo in a laboratory classroom setting. Psychopharmacol Bull. 2008; 41: 19-33.
21. Muniz R., Brams M., Mao A., McCague K., Pestreich L., Silva R. Efficacy and safety of extended-release dexmethylphenidate compared with d,l-methylphenidate and placebo in the treatment of children with attention-deficit/ hyperactivity disorder: a 12-hour laboratory classroom study. J Child Adolesc Psychopharmacol. 2008; 18: 248-256.
22. Silva RR, Muniz R., Pestreich L., et al. Efficacy and duration of effect of extended-release dexmethylphenidate versus placebo in schoolchildren with attention-deficit/ hyperactivity disorder. J Child Adolesc Psychopharmacol. 2006; 16: 239-251.
23. Weisler RH, Biederman J., Spencer TJ, Wilens TE Long-term cardiovascular effects of mixed amphetamine salts extended release in adults with ADHD. CNS Spectr. 2005; 10 (12, suppl 20). 35-43. (Pubitemid 43010496)
24. Donner R., Michaels MA, Ambrosini PJ Cardiovascular effects of mixed amphetamine salts extended release in the treatment of school-aged children with attention-deficit/hyperactivity disorder. Biol Psychiatry. 2007; 61: 706-712.
25. Wilens TE, Biederman J., Lerner M. Effects of once-daily osmotic-release methylphenidate on blood pressure and heart rate in children with attention-deficit/hyperactivity disorder: results from a one-year follow-up study. J Clin Psychopharmacol. 2004; 24: 36-41.
26. Adler LA, Spencer T., McGough JJ, Jiang H., Muniz R. Long-term effectiveness and safety of dexmethylphenidate extended-release capsules in adult ADHD. J Atten Disord. 2009; 12: 449-459.
27. Umana E., Solares CA, Alpert MA Tachycardia-induced cardiomyopathy. Am J Med. 2003; 114: 51-55.
28. Newton TF, De La Garza R. II, Kalechstein AD, Nestor L. Cocaine and methamphetamine produce different patterns of subjective and cardiovascular effects. Pharmacol Biochem Behav. 2005; 82: 90-97.
29. Laurent G., Moe G., Hu X., et al. Experimental studies of atrial fibrillation: a comparison of two pacing models. Am J Physiol Heart Circ Physiol. 2008; 294: H1206-H1215.
30. Kshirsagar AV, Carpenter M., Bang H., Wyatt SB, Colindres RE Blood pressure usually considered normal is associated with an elevated risk of cardiovascular disease. Am J Med. 2006; 119: 133-141.
31. Food and Drug Administration. E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs. 2005. http://www.fda.gov/downloads/RegulatoryInformation/Guidances/ucm129357.pdf
32. Moss AJ Measurement of the QT interval and the risk associated with QTc interval prolongation: a review. Am J Cardiol. 1993; 72: 23B-25B.
33. Singh BN, Wadhani N. Antiarrhythmic and proarrhythmic properties of QT-prolonging antianginal drugs. J Cardiovasc Pharmacol Ther. 2004; 9 (suppl 1). S85-S97.
34. Jenzer HR, Hagemeijer F. Quinidine syncope: torsade de pointes with low quinidine plasma concentrations. Eur J Cardiol. 1976; 4: 447-451.
35. Bauman JL, Bauernfeind RA, Hoff JV, Strasberg B., Swiryn S., Rosen KM Torsade de pointes due to quinidine: observations in 31 patients. Am Heart J. 1984; 107: 425-430.
36. Casis O., Espiña L., Gallego M. Effects of amphetamine on calcium and potassium currents in rat heart. J Cardiovasc Pharmacol. 2000; 36: 390-395.
37. Wakamatsu A., Nomura S., Tate Y., Shimizu S., Harada Y. Effects of methylphenidate hydrochloride on the cardiovascular system in vivo and in vitro: a safety pharmacology study. J Pharmacol Toxicol Methods. 2009; 59: 128-134.
38. Davey P. How to correct the QT interval for the effects of heart rate in clinical studies. J Pharmacol Toxicol Methods. 2002; 48: 3-9.
39. Vitiello B. Understanding the risk of using medications for attention deficit hyperactivity disorder with respect to physical growth and cardiovascular function. Child Adolesc Psychiatr Clin N Am. 2008; 17: 459-474, xi.
40. Teneggi V., Bedigian M., Vandemeulebroecke M., Pfister C., Roberts AT, Muniz R. Lack of effect of dexmethylphenidate extended release (d-MPH-ER) on QT/QTc duration in healthy subjects: a double-blind, randomized, placebo, and active controlled study. Paper presented at: The American Psychiatric Association Annual Meeting; May 3-8, 2008; Washington, DC.
41. Villalba L., Racoosin J. Safety review: follow up review of AERS search identifying cases of sudden death occurring with drugs used for the treatment of attention deficit hyperactivity disorder (ADHD). http://www.fda.gov/ohrms/ dockets/ac/06/briefing/2006-4210b-07-01-safetyreview.pdf. Accessed June 2, 2009.
42. Liberthson RR Sudden death from cardiac causes in children and young adults. N Engl J Med. 1996; 334: 1039-1044.
43. Concerta [package insert]. Fort Washington, PA: McNeil Pediatrics; 2007.
44. Daytrana [package insert]. Wayne, PA: Shire US Inc; 2008.
45. Focalin XR [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 2007.
46. Ritalin LA [package insert]. East Hanover, NJ: Novartis Pharmaceuticals Corporation; 1007.
47. Maron BJ, Thompson PD, Ackerman MJ,, et al. American Heart Association Council on Nutrition, Physical Activity, and Metabolism. Recommendations and considerations related to preparticipation screening for cardiovascular abnormalities in competitive athletes: 2007 update: a scientific statement from the American Heart Association Council on Nutrition, Physical Activity, and Metabolism: endorsed by the American College of Cardiology Foundation. Circulation. 2007; 115: 1643-1655.
48. Leslie LK, Alexander ME, Trikalinos TA, Cohen JT, Parsons SK, Newburger JW Reexamining the emperor's new clothes: ambiguities in current cardiac screening recommendations for youth with attention deficit hyperactivity disorder. Circ Cardiovasc Qual Outcomes. 2008; 1: 134-137.
49. Kimmelstiel CD, Maron BJ Role of percutaneous septal ablation in hypertrophic obstructive cardiomyopathy. Circulation. 2004; 109: 452-456.
50. Maron BJ Hypertrophic cardiomyopathy in childhood. Pediatr Clin North Am. 2004; 51: 1305-1346.
51. Maron BJ, Spirito P., Roman MJ, et al. Prevalence of hypertrophic cardiomyopathy in a population-based sample of American Indians aged 51 to 77 years (the Strong Heart Study). Am J Cardiol. 2004; 93: 1510-1514.
52. Ackerman MJ The long QT syndrome: ion channel diseases of the heart. Mayo Clin Proc. 1998; 73: 250-269.
53. Al-Khatib SM, Pritchett EL Clinical features of Wolff-Parkinson-White syndrome. Am Heart J. 1999; 138: 403-413.
54. Maron BJ, Roberts WC, Epstein SE Sudden death in hypertrophic cardiomyopathy: a profile of 78 patients. Circulation. 1982; 65: 1388-1394.
55. Knowles R., Griebsch I., Dezateux C., Brown J., Bull C., Wren C. Newborn screening for congenital heart defects: a systematic review and cost-effectiveness analysis. Health Technol Assess (Rocky). 2005; 9: 1-152, iii-iv.
56. Quaglini S., Rognoni C., Spazzolini C., Priori SG, Mannarino S., Schwartz PJ Cost-effectiveness of neonatal ECG screening for the long QT syndrome. Eur Heart J. 2006; 27: 1824-1832.
57. Wilens TE, Prince JB, Spencer TJ, Biederman J. Stimulants and sudden death: what is a physician to do ? Pediatrics. 2006; 118: 1215-1219.
58. Barkley RA, Murphy KR, Dupaul GI, Bush T. Driving in young adults with attention deficit hyperactivity disorder: knowledge, performance, adverse outcomes, and the role of executive functioning. J Int Neuropsychol Soc. 2002; 8: 655-672.
59. Cox DJ, Merkel RL, Penberthy JK, Kovatchev B., Hankin CS Impact of methylphenidate delivery profiles on driving performance of adolescents with attention-deficit/hyperactivity disorder: a pilot study. J Am Acad Child Adolesc Psychiatry. 2004; 43: 269-275.
60. Faraone SV, Biederman J., Mick E. The age-dependent decline of attention deficit hyperactivity disorder: a meta-analysis of follow-up studies. Psychol Med. 2006; 36: 159-165.
61. Biederman J., Faraone SV, Spencer T., et al. Patterns of psychiatric comorbidity, cognition, and psychosocial functioning in adults with attention deficit hyperactivity disorder. Am J Psychiatry. 1993; 150: 1792-1798.
62. de Graaf R., Kessler RC, Fayyad J., et al. The prevalence and effects of adult attention-deficit/hyperactivity disorder (ADHD) on the performance of workers: results from the WHO World Mental Health Survey Initiative. Occup Environ Med. 2008; 65: 835-842.